We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

BD DIAGNOSTIC SYSTEMS

BD Diagnostics manufactures and markets medical supplies and devices and diagnostic systems that include cellular ana... read more Featured Products: More products

Download Mobile App




Modern Methods Accurately Detect Cervical Cancer

By LabMedica International staff writers
Posted on 20 Aug 2014
Print article
Image: The BD Viper LT System for fully automated, integrated molecular testing on a table top analyzer (Photo courtesy of BD Diagnostics).
Image: The BD Viper LT System for fully automated, integrated molecular testing on a table top analyzer (Photo courtesy of BD Diagnostics).
The newer Papanicolaou test (Pap tests) and human papilloma virus (HPV) screening more accurately identify precancerous cellular changes that potentially develop into cervical cancer.

Compared to a conventional Pap tests, the newer approved process has increased detection of a significant precancerous condition by more than 64%, by making the cervical cells easier to see as the new liquid-based Pap test produces better results for screening and detecting cervical cancer and its precursors.

A clinical trial is underway at the Jersey Shore University Medical Center (Jersey City, NJ, USA) to detect the strains of HPV that lead to cervical cancer. HPV is present in more than 99% of women who develop cervical cancer. Newer DNA-based technology has also proven to be up to 40% more accurate than traditional Pap tests. Patients will have cancer causing HPV strains tested from the liquid-based Pap specimen to determine if either one or both tests will improve cancer detection. In order to be eligible to participate, women must be at least 21 years of age or older and have not had a Pap test in the past four months or a hysterectomy.

The scientists are using an HPV screening test (BDS-USHPV) designed to be used with BD Viper LT system and the BD SurePath liquid-based Pap test (BD Diagnostic; Burlington, NC, USA). The American Cancer Society (Atlanta, GA, USA) predicts that this year in the USA, more than 12,100 women will be diagnosed with cervical cancer, and roughly 4,220 women will die of the disease. When treated early, the chances of effectively treating and curing cervical cancer increase dramatically.

Mark Martens, MD, the study leader, said, “After decades of women going to their doctor for annual Pap tests, the FDA, in a historic decision in April 2014, approved HPV testing as a replacement for the Pap test. Because of this new option for patients, more tests are now being developed to further expand the options for women and we are excited to be a part of this new, more accurate, more sensitive, and more comfortable method to prevent cancer in women. It’s a groundbreaking development that provides women in our community with access to the best cervical health screening available today.”

Related Links:

Jersey Shore University Medical Center
BD Diagnostic
American Cancer Society


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.